155 related articles for article (PubMed ID: 38073379)
1. Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma.
Attia AS; Hussein S; Sameh H; Khalil A; Waley AB; Matar I; Sameh R
Cancer Biomark; 2024; 39(3):211-221. PubMed ID: 38073379
[TBL] [Abstract][Full Text] [Related]
2. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
3. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.
Bychkov A; Sampatanukul P; Shuangshoti S; Keelawat S
Pathology; 2016 Aug; 48(5):425-33. PubMed ID: 27311870
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.
Yang X; Hu Y; Shi H; Zhang C; Wang Z; Liu X; Chen H; Zhang L; Cui D
Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2127-2134. PubMed ID: 29951933
[TBL] [Abstract][Full Text] [Related]
5. Application of chemokine CXC motif ligand 12 as a novel diagnostic marker in preoperative fine-needle aspiration biopsy for papillary thyroid carcinoma.
Jung YY; Park IA; Kim MA; Min HS; Won JK; Ryu HS
Acta Cytol; 2013; 57(5):447-54. PubMed ID: 24021782
[TBL] [Abstract][Full Text] [Related]
6. MiR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12.
Dong S; Jin M; Li Y; Ren P; Liu J
Oncol Rep; 2016 Apr; 35(4):2151-8. PubMed ID: 26847706
[TBL] [Abstract][Full Text] [Related]
7. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.
Addati T; Achille G; Centrone M; Petroni S; Popescu O; Russo S; Grammatica L; Simone G
Cytopathology; 2015 Oct; 26(5):303-11. PubMed ID: 25164548
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic significance of trophoblast cell-surface antigen-2 expression in benign and malignant thyroid lesions.
Sadullahoğlu C; Sayıner A; Süren D; Yıldırım HT; Nergiz D; Sezer C; Oruç MT
Indian J Pathol Microbiol; 2019; 62(2):206-210. PubMed ID: 30971541
[TBL] [Abstract][Full Text] [Related]
9. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.
Tunca F; Sormaz IC; Iscan Y; Senyurek YG; Terzioglu T
J Endocrinol Invest; 2015 Dec; 38(12):1327-34. PubMed ID: 26280320
[TBL] [Abstract][Full Text] [Related]
10. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
11. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
12. Incidentally Discovered Papillary Thyroid Microcarcinomas Are More Frequently Found in Patients with Chronic Lymphocytic Thyroiditis Than with Multinodular Goiter or Graves' Disease.
Paparodis RD; Karvounis E; Bantouna D; Chourpiliadis C; Chourpiliadi H; Livadas S; Imam S; Jaume JC
Thyroid; 2020 Apr; 30(4):531-535. PubMed ID: 31950881
[No Abstract] [Full Text] [Related]
13. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
14. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
[TBL] [Abstract][Full Text] [Related]
15. Can noninvasive follicular thyroid neoplasm with papillary-like nuclear features be distinguished from classic papillary thyroid carcinoma and follicular adenomas by fine-needle aspiration?
Brandler TC; Zhou F; Liu CZ; Cho M; Lau RP; Simsir A; Patel KN; Sun W
Cancer Cytopathol; 2017 Jun; 125(6):378-388. PubMed ID: 28296267
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
17. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.
Hu J; Li C; Liu C; Zhao S; Wang Y; Fu Z
Cancer Biomark; 2017; 18(1):87-94. PubMed ID: 28085013
[TBL] [Abstract][Full Text] [Related]
18. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
19. Cytologic features of focal papillary thyroid carcinoma arising within follicular adenoma: a masked cytomorphologic analysis of 17 cases.
Ono JC; Wilbur DC; Lee H; Yang J; Krane JF; Bongiovanni M; Faquin WC
Acta Cytol; 2011; 55(6):531-8. PubMed ID: 22156462
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]